D. Boral Capital Reaffirms Buy Rating for NeuroSense Therapeutics (NASDAQ:NRSN)

NeuroSense Therapeutics (NASDAQ:NRSN)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $14.00 target price on the stock.

A number of other brokerages have also issued reports on NRSN. Wall Street Zen raised shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of NeuroSense Therapeutics in a report on Monday, December 29th. Finally, Roth Mkm began coverage on shares of NeuroSense Therapeutics in a report on Tuesday, March 10th. They set a “buy” rating and a $3.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, NeuroSense Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $8.50.

NeuroSense Therapeutics Price Performance

NASDAQ:NRSN traded up $0.03 during mid-day trading on Wednesday, hitting $0.76. 33,443 shares of the company’s stock traded hands, compared to its average volume of 216,974. The firm has a 50 day moving average of $0.90 and a two-hundred day moving average of $1.01. NeuroSense Therapeutics has a 12 month low of $0.63 and a 12 month high of $2.60.

Hedge Funds Weigh In On NeuroSense Therapeutics

Hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC boosted its stake in NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after buying an additional 45,450 shares in the last quarter. Jane Street Group LLC acquired a new position in NeuroSense Therapeutics during the second quarter worth $54,000. Two Sigma Investments LP bought a new position in shares of NeuroSense Therapeutics during the third quarter valued at $26,000. Finally, Yorkville Advisors Global LP bought a new position in shares of NeuroSense Therapeutics during the fourth quarter valued at $77,000. 1.04% of the stock is owned by institutional investors and hedge funds.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.